Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065
Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CDK drug has shown that it can successfully stabilize disease in advanced cancers. After positive results now the drug will further be taken into a trial in combination with AbbVie’s expected to be leukemia blockbuster Venclexta.
Lysogene delays phase 3 study of Sanfilippo gene therapy
Lysogene’s pivotal Sanfilippo syndrome trial is pushed back by a manufactu...
